Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Behav Pharmacol. 2010 Mar;21(2):135–143. doi: 10.1097/FBP.0b013e328337be7e

Figure 4. Effects of 10 mg/kg PRA and 5 mg/kg APO on PPI and startle magnitude (inset) across varying prepulse intensities in C57BL/6J mice (Exp. 4).

Figure 4

PRA was administered at a maximum dose of 10 mg/kg for comparison against 5 mg/kg of APO with the same test parameters used in Exp.1. 10 mg/kg PRA demonstrated evidence of bioactivity via startle reduction with no change in PPI, and APO served as a positive control of dopamine agonist-induced PPI disruption. Data are mean ± SEM. *p < 0.0001, #p < 0.009, ˆp < 0.04. (n = 9 mice per dose group)